한글목차

혈전 성향 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 181억 8,000만 달러에서 2026년에는 196억 달러에 이르고, CAGR 7.8%로 성장할 전망입니다. 지난 수년간의 성장은 유전성 혈액질환의 유병률 증가, 혈전 성향에 대한 낮은 인식, 병원 인프라 확충, 항응고요법의 조기 도입, 심혈관질환 발생률 증가 등이 원인으로 추정됩니다.

혈전 성향 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 265억 달러에 이르고, CAGR은 7.8%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 유전자 검사 서비스 확대, AI 기반 진단 도구 도입, 원격 의료 플랫폼 통합, 재택 항응고제 관리의 성장, 신흥 시장에서의 헬스케어 지출 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 개인 맞춤형 항응고 치료, 혈전 성향에 대한 유전자 검사 증가, 혈액 응고 장애에 대한 고급 진단 검사, 혈액 질환에 대한 인식 제고 프로그램 증가, 혈전 성향 관리에 있어 원격 의료의 통합 등을 들 수 있습니다.

혈전 성향 질환의 유병률 증가는 향후 몇 년 동안 혈전 성향 소인 시장의 성장을 견인할 것으로 예측됩니다. 혈전 성향성 소인(일반적으로 혈전 성향성 소인이라고 함)은 혈전(혈전 성향)을 형성하는 경향이 높아지는 것이 특징인 질환군입니다. 이러한 상태는 진단 방법, 치료 옵션, 진행 중인 연구에 영향을 미치며 혈전 성향 소인 시장에 큰 영향을 미칩니다. 예를 들어, 2025년 7월 PubMed의 보고에 따르면, V인자 라이덴 돌연변이와 프로트롬빈 G20210A 돌연변이는 각각 2.35와 2.62의 풀 오즈비(OR)로 사산의 위험을 현저히 증가시키는 것으로 나타났습니다. 본 조사에서는 혈전성 소인 돌연변이와 항트롬빈 결핍증 사이에 양의 상관관계가 있는 것으로 나타났습니다. 이처럼 혈전성 소인 질환의 유병률 증가가 혈전성 소인 치료 시장의 확대를 견인하고 있습니다.

혈전성 소인 시장의 주요 기업들은 치료 지속성 향상, 투여 횟수 감소, 환자 순응도 강화 등 증가하는 수요에 대응하기 위해 응고인자 대체요법에서 지속형 융합단백질 요법 등 혁신적인 치료법 개발에 주력하고 있습니다. 이러한 지속형 치료제는 응고인자와 운반체 단백질 또는 Fc 단편을 결합하여 혈액 내 반감기를 연장하고, 기존 치료법에 비해 투여 빈도를 줄임과 동시에 환자의 전반적인 삶의 질(QOL)을 개선합니다. 예를 들어, 2023년 5월 캘리포니아대학교 샌디에이고 캠퍼스 연구진은 응고인자의 안정성과 반감기를 향상시키는 획기적인 기술인 'Eloctate'를 발표했습니다. 이 기술을 기존 치료제와 결합하여 투여 빈도를 줄인 지속형 치료제 개발을 목표로 환자의 복약 순응도 및 삶의 질 향상을 도모하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Thrombophilia is a blood disorder that increases the likelihood of blood clotting in the veins and arteries, which can lead to severe complications such as heart attack, stroke, kidney failure, and pulmonary embolism. This condition can be caused by blood clotting in the arteries and veins or by an inherited (genetic) or acquired disposition.

The primary types of thrombophilia include Factor V Leiden, prothrombin 20210, antiphospholipid syndrome, and other related conditions. Factor V Leiden refers to a mutation in one of the blood-clotting factors. Common drugs used to treat thrombophilia include Heparin, Warfarin, and other anticoagulants, which are administered through various routes, such as oral and parenteral (injection). The key end-users of thrombophilia treatments include hospitals, home health agencies, specialty centers, and other healthcare facilities.

Tariffs have influenced the thrombophilia market by increasing the cost of imported diagnostic equipment, anticoagulant drugs, and laboratory reagents, particularly affecting segments such as genetic testing and anticoagulant therapy. Regions like Europe and North America, which rely on imports from Asia-Pacific, are most impacted. While tariffs have increased costs, they have also incentivized local production and innovation, enabling domestic manufacturers to expand and optimize thrombophilia solutions for local markets.

The thrombophilia market research report is one of a series of new reports from The Business Research Company that provides thrombophilia market statistics, including thrombophilia industry global market size, regional shares, competitors with a thrombophilia market share, detailed thrombophilia market segments, market trends and opportunities, and any further data you may need to thrive in the thrombophilia industry. This thrombophilia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The thrombophilia market size has grown strongly in recent years. It will grow from $18.18 billion in 2025 to $19.6 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to rising prevalence of inherited blood disorders, limited awareness of thrombophilia, growth in hospital infrastructure, early adoption of anticoagulant therapies, increasing cardiovascular disease incidences.

The thrombophilia market size is expected to see strong growth in the next few years. It will grow to $26.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to expansion of genetic testing services, adoption of AI-based diagnostic tools, integration of telehealth platforms, growth in homecare anticoagulant management, increasing healthcare expenditure in emerging markets. Major trends in the forecast period include personalized anticoagulant therapy, increased genetic screening for thrombophilia, advanced diagnostic testing for blood clotting disorders, rise in awareness programs for blood disorders, integration of telemedicine in thrombophilia management.

The rising prevalence of thrombophilic conditions is expected to drive the growth of the thrombophilia market in the coming years. Thrombophilic diseases, commonly referred to as thrombophilia, are a group of disorders characterized by an increased tendency to develop blood clots (thrombosis). These conditions significantly influence the thrombophilia market, impacting diagnostic methods, treatment options, and ongoing research. For example, in July 2025, PubMed reported that Factor V Leiden and prothrombin G20210A mutations significantly increase the risk of stillbirth, with a pooled odds ratio (OR) of 2.35 and 2.62, respectively. The study also found a positive correlation between thrombophilic mutations and antithrombin deficiency. As such, the growing prevalence of thrombophilic conditions is driving the market for thrombophilia treatments.

Key companies in the thrombophilia market are increasingly focusing on developing innovative therapies, such as long-acting fusion protein therapies for coagulation factor replacement, to address the growing demand for better treatment durability, fewer administrations, and enhanced patient compliance. These long-acting therapies combine coagulation factors with carrier proteins or Fc fragments to extend their half-life in the bloodstream, reduce the frequency of dosing compared to traditional treatments, and improve overall patient quality of life. For instance, in May 2023, researchers at the University of California, San Diego, introduced Eloctate, a groundbreaking technology that enhances the stability and half-life of coagulation factors. By combining this technology with existing therapies, they aim to create long-acting treatments that require less frequent administration, improving patient adherence and quality of life.

In March 2025, Tempus AI, a US-based provider of AI-driven precision medicine and oncology diagnostics, acquired Ambry Genetics for an undisclosed amount. This acquisition is intended to expand Tempus' genetic diagnostics portfolio and integrate Ambry's expertise in hereditary testing, including diagnostics for inherited conditions like thrombophilia, as well as cardiology, neurology, and rare diseases.

Major companies operating in the thrombophilia market are Pfizer Inc., F. Hoffmann-La Roche Limited, Fresenius Kabi AG, Hikma Pharmaceuticals PLC., Novartis AG, Shenzhen Hepalink Pharmaceutical Group Co. Limited, Teva Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim GmbH, Instrumentation Laboratory SpA, Johnson & Johnson, Bristol-Myers Squibb, Roche, Abbott, C. H. Boehringer Sohn, Portola Pharmaceuticals, Daiichi Sankyo, Bayer Group, CSL Behring, Merck & Co Inc., Janssen Pharmaceuticals

North America was the largest region in the thrombophilia market in 2025. The regions covered in the thrombophilia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the thrombophilia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thrombophilia market consists of sales of rivaroxaban, apixaban, and thrombolytics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thrombophilia Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses thrombophilia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thrombophilia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The thrombophilia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Factor V Leiden; Prothrombin 20210; Antiphospholipid Syndrome; Other Type
• 2) By Drugs: Heparin; Warfarin; Other Drugs
• 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administration
• 4) By End-Users: Hospitals; Homecare; Specialty Centers; Other End Users
• Subsegments:
• 1) By Factor V Leiden: Genetic Testing; Anticoagulant Therapy
• 2) By Prothrombin 20210: Genetic Testing; Anticoagulant Therapy
• 3) By Antiphospholipid Syndrome: Antiphospholipid Antibody Testing; Anticoagulant Therapy
• 4) By Other Types: Protein C Deficiency; Protein S Deficiency; Antithrombin III Deficiency
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Limited; Fresenius Kabi AG; Hikma Pharmaceuticals PLC.; Novartis AG; Shenzhen Hepalink Pharmaceutical Group Co. Limited; Teva Pharmaceutical Industries Limited; Sanofi SA; Boehringer Ingelheim GmbH; Instrumentation Laboratory SpA; Johnson & Johnson; Bristol-Myers Squibb; Roche; Abbott; C. H. Boehringer Sohn; Portola Pharmaceuticals; Daiichi Sankyo; Bayer Group; CSL Behring; Merck & Co Inc.; Janssen Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Thrombophilia Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Thrombophilia Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Thrombophilia Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Thrombophilia Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystem
• 4.2. Major Trends
  • 4.2.1 Personalized Anticoagulant Therapy
  • 4.2.2 Increased Genetic Screening For Thrombophilia
  • 4.2.3 Advanced Diagnostic Testing For Blood Clotting Disorders
  • 4.2.4 Rise In Awareness Programs For Blood Disorders
  • 4.2.5 Integration Of Telemedicine In Thrombophilia Management

5. Thrombophilia Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Homecare
• 5.3 Specialty Centers
• 5.4 Diagnostic Laboratories
• 5.5 Research Institutes

6. Thrombophilia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Thrombophilia Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Thrombophilia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Thrombophilia Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Thrombophilia Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Thrombophilia Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Thrombophilia Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Thrombophilia Market Segmentation

• 9.1. Global Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Factor V Leiden, Prothrombin 20210, Antiphospholipid Syndrome, Other Type
• 9.2. Global Thrombophilia Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Heparin, Warfarin, Other Drugs
• 9.3. Global Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Parenteral, Other Route Of Administration
• 9.4. Global Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Centers, Other End Users
• 9.5. Global Thrombophilia Market, Sub-Segmentation Of Factor V Leiden, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Genetic Testing, Anticoagulant Therapy
• 9.6. Global Thrombophilia Market, Sub-Segmentation Of Prothrombin 20210, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Genetic Testing, Anticoagulant Therapy
• 9.7. Global Thrombophilia Market, Sub-Segmentation Of Antiphospholipid Syndrome, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antiphospholipid Antibody Testing, Anticoagulant Therapy
• 9.8. Global Thrombophilia Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Protein C Deficiency, Protein S Deficiency, Antithrombin III Deficiency

10. Thrombophilia Market Regional And Country Analysis

• 10.1. Global Thrombophilia Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Thrombophilia Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Thrombophilia Market

• 11.1. Asia-Pacific Thrombophilia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Thrombophilia Market

• 12.1. China Thrombophilia Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Thrombophilia Market

• 13.1. India Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Thrombophilia Market

• 14.1. Japan Thrombophilia Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Thrombophilia Market

• 15.1. Australia Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Thrombophilia Market

• 16.1. Indonesia Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Thrombophilia Market

• 17.1. South Korea Thrombophilia Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Thrombophilia Market

• 18.1. Taiwan Thrombophilia Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Thrombophilia Market

• 19.1. South East Asia Thrombophilia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Thrombophilia Market

• 20.1. Western Europe Thrombophilia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Thrombophilia Market

• 21.1. UK Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Thrombophilia Market

• 22.1. Germany Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Thrombophilia Market

• 23.1. France Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Thrombophilia Market

• 24.1. Italy Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Thrombophilia Market

• 25.1. Spain Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Thrombophilia Market

• 26.1. Eastern Europe Thrombophilia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Thrombophilia Market

• 27.1. Russia Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Thrombophilia Market

• 28.1. North America Thrombophilia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Thrombophilia Market

• 29.1. USA Thrombophilia Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Thrombophilia Market

• 30.1. Canada Thrombophilia Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Thrombophilia Market

• 31.1. South America Thrombophilia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Thrombophilia Market

• 32.1. Brazil Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Thrombophilia Market

• 33.1. Middle East Thrombophilia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Thrombophilia Market

• 34.1. Africa Thrombophilia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Thrombophilia Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Thrombophilia Market Regulatory and Investment Landscape

36. Thrombophilia Market Competitive Landscape And Company Profiles

• 36.1. Thrombophilia Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Thrombophilia Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Thrombophilia Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. F. Hoffmann-La Roche Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Hikma Pharmaceuticals PLC. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

37. Thrombophilia Market Other Major And Innovative Companies

• Shenzhen Hepalink Pharmaceutical Group Co. Limited, Teva Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim GmbH, Instrumentation Laboratory SpA, Johnson & Johnson, Bristol-Myers Squibb, Roche, Abbott, C. H. Boehringer Sohn, Portola Pharmaceuticals, Daiichi Sankyo, Bayer Group, CSL Behring, Merck & Co Inc.

38. Global Thrombophilia Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Thrombophilia Market

40. Thrombophilia Market High Potential Countries, Segments and Strategies

• 40.1 Thrombophilia Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Thrombophilia Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Thrombophilia Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer